Share

    


Home / Search Results

Search Results

You searched for:

    Displaying results 1 - 20 of 27
  • 1
  • 2
  • »
The first post in ACCC's "Subspeciality Immuno-Oncology Insights" series—the APP perspective and real-world strategies for tackling current challenges in the delivery of immunotherapies for cancer.
In recognizing Cancer Immunotherapy Month and National Cancer Survivors Day (June 5), ACCC is highlighting the resources it has created to assist the multidisciplinary team in creating and adapting survivorship care plans to meet these patients’ unique needs and support toxicity management for better outcomes.
I M M U N O - ONCOLOGY I N S T I T U T E ASSOCIATION OF COMMUNITY CANCER CENTERS To help community oncology programs and practices across the United States better integrate immunotherapies to treat cancer, the Association of Community Cancer Centers (ACCC) hosted a day-long, expert faculty-driven workshop with three Member Programs: Grand Valley Oncology in Grand Junction, …
Recent advances in immuno-oncology (IO) therapies have led to rapid, effective treatments for subsets of patients with cancers that have proven resistant to conventional treatments.
SARS-CoV-2 and the resulting respiratory tract infection COVID-19 has upended our society and forcefully changed the way we care for patients. Since the emergence of the virus in early 2020, there have been questions surrounding the risk posed to patients with a cancer diagnosis and the safety of anticancer therapies.
Presented at the SITC Annual Conference.
Presented at the 2020 JADPRO Live Virtual Meeting.
In recognition of Cancer Immunotherapy Month, ACCCBuzz talked to Sigrun Hallmeyer, MD, the chair of the ACCC Immuno-Oncology Institute’s Executive Committee.
In this newly published IO Whitepaper, we take a forward look at how the ACCC IO Institute meets the needs of the evolving multidisciplinary cancer care team and other interdisciplinary providers who may be involved in caring for patients treated with immunotherapies for cancer.
For perspective on the impact of COVID-19 on clinical trials research in the area of immunotherapy, ACCCBuzz spoke with Joanne Riemer, Research Oncology Nurse at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital in Baltimore, Maryland. Joanne is a senior research oncology nurse in the Upper Aero-digestive Team. In January 2011, she was asked to work with the immunology group on …
In order to explore experiences and needs concerning cancer survivorship from both the provider and the patient perspectives, ACCC and NCCS partnered to field two online surveys to oncology providers and cancer survivors, respectively.
Immuno-oncology (IO) has radically altered the patient care paradigm. One of most important changes attributed to IO is improvement in outcomes and lengthening of survival. This good news comes with multiple challenges, not least of which is the need for new and better communication and coordination among multiple specialties over time.
Early symptom management is key to improving quality of life for patients with cancer, and proactive monitoring delivers unparalleled survival advantage while decreasing emergency visits and admissions. However, immunotherapies require special attention and procedures. Sidney Kimmel Cancer Center earned a 2018 ACCC Innovator Award for their immunotherapy triage algorithms, which provide non-oncology …
The human gastrointestinal tract is inhabited by a diverse population of bacteria that play a crucial role in maintaining homeostasis both within the gut and within the body. How much do we know about the gut microbiome as it relates to cancer treatment?
In the current oncology clinical trials landscape, many barriers remain to clinical trial enrollment that affect both the oncologist and the patient. Among these are trial locations, strict eligibility requirements, insufficient resources to support appropriate clinical trial education and screening, as well as patient and provider attitudes about trials.
Pseudoprogression has emerged as a distinct radiologic response pattern best defined as radiologic tumor progression from baseline that is not confirmed as progression on subsequent radiologic assessment.
Hyperprogressive disease (HPD) has recently been reported as a novel pattern of aggressive tumor growth following exposure to immune checkpoint blockade drugs such as anti-PD-1 and anti-PD-L1 antibodies.
ACCC 2018 Innovator Award Winner Sidney Kimmel Cancer Center at Jefferson Health in Philadelphia, PA, has implemented new tools and processes to deliver a proactive, multidisciplinary team approach to caring for patients on cancer immunotherapies via continuous symptom monitoring and effective management of immune-related adverse events. Guest blogger Tracy Virgilio, RN, MSN, CCRC, OCN, describes the …
A forthright conversation between the treating clinician, patient and family members on the importance of self-reporting adverse events must take place prior to consideration of combination immunotherapy.
Survivorship care planning requires communication, care coordination, and education. Since immune-related adverse events are still being discovered, these discussions are even more imperative.
    Displaying results 1 - 20 of 27
  • 1
  • 2
  • »